Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
alkotinib (ZG0418)
i
Other names:
ZG0418, ZG 0418, ZG-0418
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Suzhou Zelgen
Drug class:
ALK inhibitor, ROS1 inhibitor
Related drugs:
‹
crizotinib (312)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
TQ-B3101 (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
NVL-655 (1)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
TSR-011 (0)
XZP-3621 (0)
SIM1803-1A (5)
AB-106 (5)
AGX87 (0)
XZP-5955 (0)
NVL-520 (0)
crizotinib (312)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
TQ-B3101 (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
NVL-655 (1)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
TSR-011 (0)
XZP-3621 (0)
SIM1803-1A (5)
AB-106 (5)
AGX87 (0)
XZP-5955 (0)
NVL-520 (0)
›
Associations
News
Trials
Filter by
Latest
7ms
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (clinicaltrials.gov)
P2, N=4, Terminated, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=104 --> 4 | Recruiting --> Terminated; Sponsor R&D Strategy Adjustment
7 months ago
Enrollment change • Trial termination
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • alkotinib (ZG0418)
9ms
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=17, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Completed
9 months ago
Trial completion • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Xalkori (crizotinib) • alkotinib (ZG0418)
1year
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (clinicaltrials.gov)
P2, N=104, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
1 year ago
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • alkotinib (ZG0418)
over1year
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
over 1 year ago
Trial completion date • Trial primary completion date • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Xalkori (crizotinib) • alkotinib (ZG0418)
almost2years
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (clinicaltrials.gov)
P2, N=104, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
almost 2 years ago
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • alkotinib (ZG0418)
almost2years
A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
almost 2 years ago
Trial completion date • Trial primary completion date • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Xalkori (crizotinib) • alkotinib (ZG0418)
over3years
A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
over 3 years ago
Clinical • Trial completion date • Trial primary completion date
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Xalkori (crizotinib) • alkotinib (ZG0418)
over4years
A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=18, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: May 2020 --> May 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
over 4 years ago
Clinical • Trial completion date • Trial primary completion date
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Xalkori (crizotinib) • alkotinib (ZG0418)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login